Sanger Institute looks to the future

Following the completion of the first draft of the Human Genome the Sanger Institute looks to the post-genomic future.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Wellcome Trust Sanger Institute is moving into the post-genomic era with a new five-year £300 million plan. Under the leadership of Allan Bradley, the Institute will concentrate on gene function, cancer genomics, and the genomes of model organisms such as the mouse and the zebrafish.

Funded by the Wellcome Trust — the World's largest biomedical charity — the Institute is a leading player in the Human Genome Project Consortium and was responsible for unravelling one third of the human genome. A 'working draft' of the genome was published earlier this year, but the work goes on — with the finished sequence expected by 2003. The Sanger Institute will build on the genome investment with new research on gene function and control. In the coming year, one third of the Institute's £63.3 million funding is earmarked for new projects. "The funding is a very strong commitment to our work by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Susan Aldridge

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours